arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

download Export Data

Alamar Biosciences, Inc.

ALMR

$32.14 ▼ -1.08 (-3.24%) at close

5 Visible periods

25 Metrics

Peer-ranked Benchmarks

Price Chart

insights

Verdict pending

Sync financial data to generate a health grade for this company.

auto_awesome

Analytical Summary

Review the statement evidence below to form a view on ALMR.

Market Cap $1.9B

Dividend Yield —

Revenue Growth 82.1% ↘

Op. Margin -46.0% ↗

ROIC -4.3% ↘

FCF / Share $-0.26 ↗

Trailing P/E —

Price / Book 6.0x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Sep 23, 2026.

5-Year Financial Trajectory

Quarterly

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$29.43M

↑ +82.1% —

Net Income Profit after all expenses

$-21.32M

↓ -178.4% —

Operating Margin Operating profit as % of sales

-46.0%

↑ +3.0% —

FCF / Share Free cash flow per share

$-0.26

↑ +77.0% —

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 4 metrics

Metric	Q2 FY2026 Jun 30, 2026 10-Q ↗	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗
Revenue Growth YoY (%)	82.1% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+1542%)	98.9% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+1878%)	—	—	—
EPS Growth YoY (%)	64.5% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	-155.9% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	—	—
Net Income Growth YoY (%)	-178.4% Weak Weak Year-over-year change in net income	-178.4% Weak Weak Year-over-year change in net income	—	—	—
FCF Growth YoY (%)	77.0% Excellent Excellent Year-over-year change in free cash flow	-41.2% Weak Weak Year-over-year change in free cash flow	—	—	—

💰 Are margins durable? 5 metrics

Metric	Q2 FY2026 Jun 30, 2026 10-Q ↗	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗
Operating Margin (%) (%)	-46.0% Weak → Weak Stable Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-483%)	-47.4% Weak ↑ Weak Improving Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-495%)	—	-49.0% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-508%)	-65.3% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-644%)
Effective Tax Rate (%) (%)	0.7% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	-2.2% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	—	—
Profit Margin (%) (%)	-72.5% Weak ↓ Weak Declining Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1006%)	-81.9% Weak ↓ Weak Declining Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1124%)	—	-47.4% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-692%)	-58.5% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-831%)
FCF Margin (%) (%)	-50.9% Weak ↑ Weak Improving Free cash flow as a percentage of revenue Optimal: > 10%	-80.5% Weak ↑ Weak Improving Free cash flow as a percentage of revenue Optimal: > 10%	—	-78.2% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	-104.1% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%
FCF / Net Income (x)	0.70x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.98x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	—	1.65x Excellent Excellent Free cash flow relative to reported net income Optimal: > 1x	1.78x Excellent Excellent Free cash flow relative to reported net income Optimal: > 1x

🎯 Is capital allocation efficient? 3 metrics

Metric	Q2 FY2026 Jun 30, 2026 10-Q ↗	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗
Return on Invested Capital (%)	-4.3% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	7.1% Fair Fair Return earned on debt + equity capital invested Optimal: > 10%	—	—	—
Return on Capital (%) (%)	-3.5% Weak Weak Operating profit relative to total assets Optimal: > 10%	-6.6% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—	—
Return on Common Equity (%) (%)	-6.8% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-145%)	12.0% Fair Fair Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-20%)	—	—	—

⚖️ Is the balance sheet risky? 2 metrics

Metric	Q2 FY2026 Jun 30, 2026 10-Q ↗	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗
Interest Coverage (x)	-92.05x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-79.15x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	—	-2639.67x Weak Weak Operating income divided by interest expense Optimal: > 5x	-2851.00x Weak Weak Operating income divided by interest expense Optimal: > 5x
Net Debt (USD)	$-132.97M	$-64.59M	$-30.00M	—	—

📊 What does each share earn? 6 metrics

Metric	Q2 FY2026 Jun 30, 2026 10-Q ↗	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗
Revenue per Share (USD)	$0.50	$2.12	—	$1.42	$1.16
Basic EPS, GAAP (USD)	$-0.22	$-1.74	—	$-0.62	$-0.68
Free Cash Flow per Share (USD)	$-0.26	$-1.71	—	$-1.11	$-1.21
Book Value per Share (USD)	$5.33	$-14.52	—	—	—
Tangible Book Value per Share (USD)	$5.33	$-14.52	—	—	—
Basic Weighted Avg Shares (shares)	58.67M	12.26M	—	11.41M	11.26M

🏦 How resilient is the balance sheet? 2 metrics

Metric	Q2 FY2026 Jun 30, 2026 10-Q ↗	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗
Working Capital (USD)	$303.42M	$117.42M	$70.97M	—	—
Total Equity (USD)	$312.86M	$-178.07M	$-158.95M	—	—

📋 What is driving earnings? 3 metrics

Metric	Q2 FY2026 Jun 30, 2026 10-Q ↗	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗
Sales/Revenue/Turnover (USD)	$29.43M	$26.04M	—	$16.16M	$13.09M
Net Income, GAAP (USD)	$-21.32M	$-21.32M	—	$-7.66M	$-7.66M
Operating Cash Flow (USD)	$-11.32M	$-20.35M	—	$-11.88M	$-13.07M

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday

Alamar Biosciences, Inc.

Analytical Summary

5-Year Financial Trajectory

Statement lens

Benchmark Lens

Compare ALMR with peers